German report on benefit assessment a miss for drug industry; HTA grants strongest endorsement yet
This article was originally published in SRA
Executive Summary
A government report on the tough pricing and reimbursement system that Germany introduced under the AMNOG healthcare reform act has failed to address key problems with the system, according to Matthias Heck, Brussels representative for the BPI, a German pharmaceutical industry association. Separately, a drug has recently won the strongest endorsement yet from German health technology appraisal institute IQWiG for a product passing through the AMNOG system1-3.